for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up
Healthcare

BRIEF-Vir and Alnylam Identify RNAi Therapeutic Development Candidate for the Treatment of COVID-19

May 4 (Reuters) - Alnylam Pharmaceuticals Inc:

* VIR AND ALNYLAM IDENTIFY RNAI THERAPEUTIC DEVELOPMENT CANDIDATE, VIR-2703 (ALN-COV), TARGETING SARS-COV-2 FOR THE TREATMENT OF COVID-19

* ALNYLAM PHARMACEUTICALS INC - COMPANIES EXPECT TO START HUMAN CLINICAL TRIALS AT OR AROUND YEAR-END 2020

* ALNYLAM PHARMACEUTICALS INC - PLAN TO SOON MEET WITH FDA TO DISCUSS A POTENTIAL ACCELERATED PATH FOR FILING IND AT OR AROUND YEAR-END 2020 Source text for Eikon: Further company coverage:

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up